UGT2B17 and osteoporosis: However, the role of polymorphism in UGT2B17 remains controversial since the deletion polymorphism of UGT2B17 was found to be associated with lung cancer, osteoporosis, prostate cancer, and endometrial cancer [9, 11, 25, 26] while there are also studies to relate the duplication polymorphism with lower BMD, thinner CT, higher BR, and osteoporosis [25].